The final day of 2025 Formula 1 pre-season testing concluded on Friday at the Sakhir Circuit in Bahrain. Running was split ...

Novartis (NYSE:NVS) announced Friday that the European Medicines Agency (EMA), endorsed Fabhalta for the treatment of adults ...

C3 AI (NYSE: AI), the Enterprise AI application software company, today announced that C3 AI Chairman and CEO Thomas M.

A new study highlights the importance of normal serology in reducing severe and renal flares in systemic lupus erythematosus ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

The 2025 F1 season gets underway this week as Bahrain hosts the official three-day pre-season test for all 10 teams. It is ...

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacopl ...

C3.ai, Inc. (AI) stock plunged nearly 10% on Thursday despite the enterprise artificial intelligence software applications ...

Apple's new 'e' series smartphone could be a regular thing: new iPhone 16e would be followed up by iPhone 17e in 2026 with in ...

Shares of C3.ai ( AI -6.27%) are falling on Thursday. The company's stock had lost 6.4% as of 2:10 p.m. ET, but was down as ...

Carlos Sainz set the pace for Williams ahead of Ferrari pair Lewis Hamilton and Charles Leclerc, as rain impacted the second ...